(gallium (68Ga) oxodotreotide injection)

This information is intended only for Healthcare Professionals in Canada. Canadian regulations limit the scope of information we can provide to the public for marketed products. If you are a member of the public and have any questions about this product, please consult a qualified healthcare professional for further information.

NETVision® (gallium (68Ga) oxodotreotide injection) is a marketed diagnostic radiopharmaceutical used to non-invasively detect and localize somatostatin receptor (SSTR)-positive neuroendocrine tumours (NETs). The agent is used with positron emission tomography (PET) as an adjunct to other diagnostic tests (e.g. Computerized Tomography (CT) or Magnetic Resonance Imaging (MRI)).

Neuroendocrine tumours (NETs) are the second most common neoplasm of the diffuse endocrine system and are a diverse and uncommon group of malignancies with an incidence of approximately 2 – 6/100,000 in Canada. NETVision® exploits the overexpression of SSTRs as a specific target for diagnostic purposes and for localization of NETs, including in the gastroenteropancreatic tract, respiratory system, thyroid, and presenting as pheochromocytomas and paraganglioma.

Product Information

Indications and Clinical Use

NETVision® (gallium (68Ga) oxodotreotide injection) is indicated for use with positron emission tomography (PET), as an adjunct to other diagnostic tests, for the detection and localization of somatostatin receptor-positive neuroendocrine tumours (NETs).


Route of Administration:

  • Intravenous

Dosage Form/Strength/Composition:

  • Solution for Injection
  • ≤ 122 MBq/mL (radioactive strength at end of synthesis)
  • ≤ 50 μg 68Ga-oxodotreotide peptide (chemical dose)

Non-medicinal Ingredients:

  • Phosphate-buffered saline, ≤ 10% ethanol


  • Patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see the NETVision® Product Monograph (Section 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING).
  • Patients who are taking disulfiram (Antabuse)